P
Petrichor
Petrichor is a Series A to growth stage investment firm. It has made 8 investments. 33% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (44% of deals). Average disclosed round size is $83.9M (across 8 rounds with reported amounts).
Portfolio
8
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
Aaron Kantoff
Founder, Managing Partner Scion
Samuel Hall, PhD
Founder, Managing Partner Scion
Tadd Wessel
Founder and Managing Partner
Andreas Loew, PhD
Partner
Don Hardison
Petrichor Operating Partner
Michael Beecham
Partner
Patrick Lally
Partner
Paul Sekhri
Petrichor Operating Partner
Eidul Hossein
Director of Finance
Megan Blewett
Principal
Lucy Burke
Senior Associate
Andrew Davis
Associate
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
9 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Geneoscopy | Series C | $105M | Jan 2025 |
 Evergreen Theragnostics | Series A | $26M | Apr 2024 |
 Avalo Therapeutics | Unknown | $185M | Jan 2024 |
 Ascend Advanced Therapies | Series A | $132.5M | Mar 2023 |
 Vero Biotech | Growth | $30M | Jan 2023 |
| Ascend Advanced Therapies | Series A | $130M | Jan 2023 |
 Aurion | Series A | — | Jan 2022 |
| LLeukocare | Unknown | $17.5M | Jan 2021 |
| PPalvella Therapeutics, Inc. | Series C | $45M | May 2020 |
Top Co-Investors
4BIO Capital2 shared
DCVC2 shared
Abingworth LLP2 shared
Ajinomoto Group Ventures2 shared
Deerfield2 shared
Digitalis Ventures2 shared
Labcorp1 shared
Morningside1 shared
Dorm Room Fund1 shared
LIFTT1 shared
OrbiMed1 shared
Deep Track Capital1 shared
Commodore Capital1 shared
RA Capital Management1 shared
e2vc1 shared
Visionary Ventures1 shared
existing shareholders1 shared
Adams Street Partners1 shared
Last updated: 20 October 2026